Frazier Life Sciences funds (NASDAQ: KALV) disclose updated KalVista ownership
Frazier Life Sciences funds have updated their ownership in KalVista Pharmaceuticals (NASDAQ: KALV) via an Amendment No. 8 to a Schedule 13D filing. The filing details the individual stakes of various Frazier funds, including Frazier Life Sciences Public Fund, L.P. holding 2.3% of shares, and clarifies the beneficial ownership structure, particularly for general partners and investment committees. This disclosure is based on KalVista's 53,240,888 shares outstanding as of May 7, 2026.
KalVista Pharmaceuticals (KALV) CMO covers RSU taxes with 1,032-share sale
KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 1,032 shares of common stock at an average price of $26.76 per share. This sale was a "sell to cover" transaction to fulfill tax withholding obligations tied to the vesting of 2,419 Restricted Stock Units (RSUs), and was not a discretionary trade. Following these transactions, Audhya directly holds 143,934 shares of KalVista common stock.
KalVista (KALV) CEO nets RSU shares after tax-related stock sale
KalVista Pharmaceuticals CEO Benjamin L. Palleiko exercised 2,419 restricted stock units and subsequently sold 1,129 common shares at $26.76 per share. This sale was a non-discretionary "sell to cover" transaction to handle tax withholding obligations from RSU vesting. Following these transactions, Palleiko directly holds 467,665 common shares in the company.
KalVista (KALV) CDO sells shares to cover RSU tax obligations
KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 1,108 common shares at $26.76 each to cover tax obligations arising from the vesting of 1,774 restricted stock units (RSUs). This "sell to cover" transaction was non-discretionary, and after the sale, Yea directly holds 227,367 shares of KalVista common stock. The transaction details were reported in a Form 4 SEC filing.
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group for $27.00 per share. KSF is evaluating whether this price adequately values KalVista and if the process leading to the proposed sale was fair to shareholders. They are inviting shareholders who believe the offer undervalues the company to contact them regarding their legal rights.
KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47
This article reports that the price target for KalVista Pharmaceuticals (KALV) has been decreased to $30.47, representing a 12.99% reduction. No further details are provided in the snippet.
KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47
The price target for KalVista Pharmaceuticals (KALV) has been decreased by 12.99% to $30.47. This change reflects a revised outlook on the company's valuation.
The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value
Chiesi Group has acquired KalVista Pharmaceuticals for $1.9 billion, a strategic investment in the rapidly growing hereditary angioedema (HAE) market. This acquisition centers on KalVista's drug, EKTERLY (sebetralstat), the first oral, on-demand treatment for acute HAE attacks, which is seen as a significant advancement due to its convenience and efficacy. The deal highlights the increasing value placed on innovative, patient-focused therapies in rare disease markets, driving growth, particularly for oral and subcutaneous treatment options.
KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47
The article reports that the price target for KalVista Pharmaceuticals (KALV) has been decreased by 12.99%, bringing it down to $30.47. This indicates a revised outlook on the company's stock valuation by analysts.
KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47
The article reports that the price target for KalVista Pharmaceuticals (KALV) has been decreased by 12.99%, bringing it down to $30.47. No further details are provided in the snippet.
Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum
KalVista Pharmaceuticals (KALV) has seen significant share price appreciation recently, up 31% in the past month and 79% in the last three months, bringing its 1-year return to 124.06%. The stock is considered 13.8% undervalued with a fair value of $31.00 per share, largely driven by strong early uptake of its drug EKTERLY for hereditary angioedema. However, potential risks include demand normalization and payer limitations, suggesting investors should evaluate the underlying numbers and risks.
Point72 entities report 4.2% stake in KalVista (NASDAQ: KALV) — 2.14M shares
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have reported a beneficial ownership of 2,136,940 shares of KalVista Pharmaceuticals (NASDAQ: KALV) common stock, representing a 4.2% stake. This disclosure was made in an Amendment No. 2 to a Schedule 13G/A filing, with the position noted as of March 31, 2026. The shares are held by an investment fund managed by Point72 Asset Management, with shared voting and dispositive power, though the reporting persons directly own no shares.
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period
KalVista has reported $49.1 million in revenue from its drug EKTERLY during an eight-month transition period. This financial update provides insight into the drug's initial market performance.
Chiesi to acquire KalVista (NASDAQ: KALV) in $27 per share cash deal
KalVista Pharmaceuticals recorded its first major commercial quarter with $40.9 million in revenue, driven by EKTERLY sales, and simultaneously announced its acquisition by Chiesi. The all-cash deal offers KalVista shareholders $27.00 per share and is expected to close in the third quarter of 2026, subject to customary conditions and regulatory approvals. The company reported a narrowed net loss of $23.5 million and maintains a strong cash position of $285.0 million.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of
Brodsky & Smith is investigating potential breaches of fiduciary duties by the Boards of Directors of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics. These investigations concern whether the proposed acquisitions of these companies provide fair value to their respective shareholders. Shareholders of these companies are encouraged to contact Brodsky & Smith to discuss the investigations without cost or obligation.
KalVista to offer $110M in convertible notes; shares down 10%
KalVista Pharmaceuticals announced a private offering of $110 million in convertible senior notes due 2029, with an option for initial purchasers to buy an additional $16.5 million. The company plans to use the net proceeds for general corporate purposes, including clinical trials, research and development, and working capital. Following the announcement, KalVista's shares fell approximately 10%.
SilverArc (KALV) files 2.88M-share Schedule 13G stake disclosure
SilverArc Capital Management, LLC and Devesh Gandhi have disclosed a beneficial ownership of 2,876,407 shares, representing 5.6% of KalVista Pharmaceuticals Inc.'s Class A Common Stock, as of March 31, 2026, through a Schedule 13G filing. SilverArc acts as an investment adviser to several funds that collectively hold this position, indicating a passive investment. The filing details the allocation of shares across five different funds managed by SilverArc, confirming shared voting and dispositive power over the reported shares.
KalVista (KALV) CEO Palleiko sells shares to cover taxes after RSU vesting
KalVista Pharmaceuticals CEO Benjamin L. Palleiko recently reported RSU vesting and a subsequent "sell to cover" transaction. On May 11, 2026, he exercised 7,120 restricted stock units, receiving an equal number of common shares. The following day, he sold 3,322 common shares at $26.71 each to cover tax withholding obligations associated with the RSU vesting, which was not a discretionary sale. After these transactions, Palleiko directly held 466,375 common shares and had 92,560 restricted stock units still outstanding.
Kalvista Pharmaceuticals stock hits 52-week high at $26.85
Kalvista Pharmaceuticals (KALV) stock reached a new 52-week high of $26.85, reflecting a 130% total return over the past year. This surge is partly due to the company's definitive agreement to be acquired by Chiesi Group for approximately $1.9 billion, with Chiesi paying $27.00 per share. Although the stock is considered undervalued with a Fair Value of $30.36 according to InvestingPro, analysts have downgraded ratings to Neutral or Hold, aligning price targets with the acquisition offer.
Chiesi (NASDAQ: KALV) offers $27.00 per share to acquire KalVista
Chiesi Farmaceutici S.p.A., through its wholly-owned subsidiary Skyline Merger Sub, Inc., has offered to acquire all outstanding shares of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) for $27.00 per share in cash. This tender offer, detailed in a Schedule TO filing, covers approximately 53.24 million outstanding shares, along with various equity-linked instruments like options, RSUs, and warrants. The acquisition is backed by a merger agreement dated April 29, 2026, and is expected to integrate KalVista into Chiesi's rare disease portfolio.
F m Investments LLC Purchases 37,486 Shares of KalVista Pharmaceuticals, Inc. $KALV
F m Investments LLC increased its stake in KalVista Pharmaceuticals by 18.8% in the fourth quarter, purchasing an additional 37,486 shares to own a total of 236,690 shares valued at approximately $3.82 million. Despite this, several KalVista insiders, including the CEO and CFO, recently sold shares to cover tax withholding obligations. Analysts have shown caution, with multiple downgrades to "Hold," though the consensus price target for KALV remains at $30.60.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). This report was delivered via Quantisnow, a platform that provides real-time market data and news to retail investors. The company's recent analyst ratings and SEC filings are also highlighted.
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Hold Rating, Maintains Target Price $27
Stifel has reiterated its Hold rating for KalVista Pharmaceuticals (KALV.US) and maintained its target price at $27. This suggests the firm believes the stock will perform in line with the broader market.
Chiesi Continues Hunt For Rare Disease Drugs After KalVista Acquisition
Chiesi is actively pursuing further acquisitions in the rare disease space following its recent purchase of KalVista. The Italian firm expressed a desire for more competition in deal-making as it continues to expand its rare disease drug development portfolio. This strategy builds on previous rare disease ventures, including a gene therapy pact with Arbor and the acquisition of Amryt.
Chiesi to buy Kalvista, developer of HAE treatment Ekterly
Chiesi has agreed to acquire Kalvista Pharmaceuticals for approximately $1.9 billion, thereby adding Ekterly (sebetralstat), an oral on-demand treatment for hereditary angioedema (HAE) attacks, to its rare disease portfolio. The acquisition aims to expand global access to sebetralstat, which is approved in several regions and is being further developed for use in younger children. This strategic move strengthens Chiesi's presence in rare immunology and leverages Kalvista's drug discovery capabilities with Chiesi's global infrastructure.
Chiesi Deal Shapes KalVista Shareholder Outlook And Valuation Potential
Chiesi Farmaceutici S.p.A. has agreed to acquire KalVista Pharmaceuticals (NasdaqGM:KALV), which will transfer responsibility for the hereditary angioedema (HAE) treatment EKTERLY®. This acquisition represents a change in corporate control for KalVista and highlights a broader trend of larger pharmaceutical companies acquiring biotech developers. The deal is expected to cap KalVista's stock upside at the offer terms, with the company currently trading below analyst targets but significantly below its estimated fair value.
Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD
Kalvista Pharmaceuticals (KALV) stock recently hit a 52-week high of $26.77, reflecting a significant 118% increase over the past year and a 145% return in six months. The company is set to be acquired by Chiesi Group for $27.00 per share in cash, a deal valued at approximately $1.9 billion, which led to analyst downgrades to Neutral and Hold ratings.
Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista
Chiesi Farmaceutici and its subsidiary Skyline Merger Sub intend to acquire KalVista Pharmaceuticals for $27.00 per share in cash, according to a proposed cash tender offer under a Merger Agreement dated April 28, 2026. The offer has not yet commenced, with formal offer materials including Schedule TO and Schedule 14D-9 to be filed with the SEC when launched. The transaction highlights include standard offer terms and a focus on the commercial and regulatory value of KalVista's products like EKTERLY®, while also acknowledging potential risks such as FDA approvals and market adoption.
Chiesi to buy KalVista Pharmaceuticals for $1.9 billion
Chiesi Farmaceutici S.p.A. announced its intention to acquire KalVista Pharmaceuticals, Inc. for approximately $1.9 billion. This acquisition will be executed through a tender offer to acquire all outstanding shares of KalVista for a cash price per share. The deal aims to enhance Chiesi's portfolio with KalVista's leading assets in cardiovascular and rare diseases.
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal
KalVista Pharmaceuticals shares rose significantly after Italy's Chiesi Farmaceutici agreed to acquire the company in a deal valued at up to $1.9 billion. The acquisition will bolster Chiesi's rare disease pipeline, particularly with KalVista's oral drug sebetralstat for hereditary angioedema.
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal
This article reports that Italian pharmaceutical company Chiesi has agreed to acquire KalVista Pharmaceuticals in a deal valued at $1.9 billion. This acquisition is significant for KalVista, causing its stock to climb following the announcement.
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Chiesi Group is set to acquire KalVista Pharmaceuticals, a move that will expand its global rare disease portfolio. This acquisition was announced via a press release, with Quantisnow alerting its Plus members of the news shortly after publication, highlighting the real-time market data services it offers to investors.
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal
The article reports that KalVista Pharmaceuticals' stock surged after Italy's Chiesi Farmaceutici agreed to acquire the company for approximately $1.9 billion. The deal values KalVista at $10.00 per share, with an additional $3.00 per share contingent upon the approval of its hereditary angioedema drug, sebetralstat, in the U.S. and Europe. This acquisition highlights industry confidence in sebetralstat's potential as a treatment for acute HAE attacks.
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group for $27.00 per share in cash. KSF is scrutinizing whether this proposed acquisition price and the process leading to it are fair and adequate for KalVista's shareholders. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights.
Chiesi Group Agrees to Acquire KalVista for $1.9B
Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals Inc. for approximately $1.9 billion. The acquisition involves a tender offer of $27.00 per share in cash for all outstanding KalVista shares, aiming to expand Chiesi's portfolio in rare diseases. This transaction is expected to close in the third quarter of the current fiscal year.
Millennium group reports shared control of 1.9M KalVista shares (KALV)
A Schedule 13G/A amendment reveals that the Millennium group, including Millennium Management LLC and Israel A. Englander, holds shared control over 1,912,146 shares (3.7%) of KalVista Pharmaceuticals, Inc. Integrated Core Strategies (US) LLC also reports shared control over 1,546,105 shares (3.0%). The filing clarifies that these are passive investments with shared voting and dispositive power, not implying direct beneficial ownership by the reporting entities.
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright
HC Wainwright downgraded KalVista Pharmaceuticals (NASDAQ:KALV) from a "buy" to a "neutral" rating with a $27.00 price objective, following an agreement for Italian drugmaker Chiesi to acquire KalVista for approximately $1.9 billion, or $27.00 per share. Several other analysts have also lowered their ratings to "hold," and multiple shareholder law firms have launched fairness probes into the acquisition price, adding legal uncertainty to the deal. Insiders have also recently sold shares.
KalVista (NASDAQ: KALV) amends 10-KT, reveals April 29, 2026 merger deal with Chiesi
KalVista Pharmaceuticals, Inc. filed an amended 10-KT disclosure revealing that it has entered into an Agreement and Plan of Merger with Chiesi Farmaceutici S.p.A. As part of this agreement, KalVista will become a wholly owned subsidiary of Chiesi. The amendment also provides detailed information on director and executive biographies, compensation tables, equity plan information, and related-party transactions, including the participation of certain affiliates in a November 2024 offering.
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi has made its largest acquisition to date, purchasing KalVista Pharmaceuticals for approximately $1.9 billion. This deal primarily focuses on Ekterly (sebetralstat), KalVista's FDA-approved on-demand treatment for hereditary angioedema (HAE), allowing Chiesi to expand its rare disease portfolio and work towards its 2030 revenue target of €6 billion. The acquisition highlights a week of substantial dealmaking in the biopharmaceutical industry.
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) to Chiesi Group for $27.00 per share in cash. The firm is concerned that KalVista and its board may have violated federal securities laws and/or breached fiduciary duties by not securing the best price, ensuring a fair sales process, or disclosing all material information to shareholders. Halper Sadeh LLC may seek increased consideration or other benefits for shareholders.
Chiesi Group to Acquire KalVista Pharmaceuticals in $1.9 Billion Deal
Chiesi Group is set to acquire KalVista Pharmaceuticals for approximately $1.9 billion, aiming to expand its global rare disease portfolio and strengthen its U.S. presence. The deal centers on KalVista's EKTERLY® (sebetralstat), an oral on-demand treatment for hereditary angioedema (HAE), which has already secured multiple approvals and generated $49 million in sales in 2025. This acquisition, Chiesi's largest to date, is expected to accelerate global access to sebetralstat and contribute significantly to Chiesi's strategic revenue target of €6 billion by 2030.
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating KalVista Pharmaceuticals (NASDAQ: KALV) for potential breaches of fiduciary duty related to its recently announced transaction with Chiesi Group. Stockholders are set to receive $27.00 per share in cash, totaling approximately $1.9 billion in equity value, while insiders are expected to benefit substantially from change of control arrangements. The investigation focuses on whether the KalVista board fulfilled its fiduciary duties given the transaction's terms, including a significant penalty for accepting a competing bid.
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating KalVista Pharmaceuticals Inc. (NASDAQ: KALV) regarding its proposed transaction with Chiesi Group, which offers KalVista stockholders $27.00 per share in cash. The investigation focuses on potential breaches of fiduciary duty by KalVista's board of directors, particularly concerning the fairness of the price and limitations on competing bids. Ademi LLP encourages shareholders to contact them for more information about joining the investigation.
Chiesi to Acquire KalVista Pharmaceuticals in Cash Merger
Chiesi Group will acquire KalVista Pharmaceuticals for $1.9 billion in cash, paying $27 per share, which represents a 36% premium to KalVista's 30-day VWAP. This acquisition, expected to close in Q3 2026, is Chiesi's largest to date and aims to expand its rare immunology franchise, U.S. presence, and control of EKTERLY, the first oral on-demand HAE therapy. KalVista shareholders will receive an immediate cash exit, while Chiesi strengthens its portfolio and moves towards its 2030 revenue target.
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Chiesi Group announced its plan to acquire KalVista Pharmaceuticals for approximately $1.9 billion, paying $27.00 per share in cash. This acquisition will integrate KalVista's oral, on-demand treatment for hereditary angioedema (HAE), EKTERLY® (sebetralstat), into Chiesi’s rare immunology portfolio. The transaction, expected to close in Q3 2026, aims to strengthen Chiesi's commitment to rare diseases and accelerate patient access to innovative therapies like sebetralstat, which has already received approvals in several markets.
KalVista climbs on $1.9B buyout deal with Chiesi (KALV:NASDAQ)
KalVista Pharmaceuticals (KALV) saw its stock climb approximately 39% in premarket trading after Italian pharmaceutical company Chiesi Group announced an agreement to acquire the U.S. rare disease drug developer. The all-cash deal is valued at nearly $1.9 billion. This acquisition highlights a significant merger in the pharmaceutical sector.
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Italian drugmaker Chiesi has announced its agreement to acquire KalVista Pharmaceuticals for approximately $1.9 billion. This acquisition is part of Chiesi's strategy to expand its portfolio of rare disease drugs. The deal was reported on Wednesday, April 29, 2026.
Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
Chiesi Farmaceutici SpA has announced its largest acquisition to date, agreeing to buy US-listed KalVista Pharmaceuticals Inc. for approximately $1.9 billion. The Italian pharmaceutical company will acquire all of KalVista's shares for $27 each in cash, a move that expands its rare immunology portfolio. The boards of both companies have approved the transaction.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of "Moderate Buy" from Analysts
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has received a consensus "Moderate Buy" rating from analysts, with an average one-year price target of $32.60, significantly above its recent share price of $19.63. The company, a clinical-stage biotech focusing on conditions like hereditary angioedema and diabetic macular edema, has also seen notable insider selling, with a major shareholder and CFO liquidating parts of their holdings. Institutional investors and hedge funds have shown varied activity, with some increasing stakes while others adjusted positions.
KalVista prices upsized offering of $125M of 3.250% notes due 2031
KalVista Pharmaceuticals has priced an upsized offering of $125 million in 3.250% convertible senior notes due 2031. The offering includes an option for initial purchasers to buy an additional $18.75 million in notes. The company anticipates net proceeds of approximately $120.2 million, or $138.3 million if the option is fully exercised, after deducting discounts and estimated offering expenses.
